OrthoRTI extends clinical hold of biologics drug

Biologics

Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release.

Ortho-R is being studied in rotator cuff tear repair. OrthoRTI plans to enroll 78 patients for its phase 1 and 2 clinical trials in the fall.

The trial was put on hold in June, and OrthoRTI submitted data related to the drug's chemistry, manufacturing and control to the FDA in July.

Subscribe to the following topics: orthortiortho rclinical trialhold

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like